Archives — November 2017 back to current month (16)
After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.C. Wainwright & Co., provided an industry update.
Following the company's release of its latest financial report, three analysts weighed in on the results.
Analyst's 'Top Pick' Advances Vaccine Candidates (11/21/2017)
Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus.
Stock Price Jump Reflects Biotech's Active October (11/20/2017)
This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment.
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets.
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
The Lowdown on Getting High in Canada (11/14/2017)
Some 600 tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio.
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17.
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans.
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications.
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company.
Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market.
Drug Offers 'Best-in-Class' Potential (11/01/2017)
John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health.
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications.
|"DRRX intends to start a NASH trial as soon as H1/19."|
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"VIVs recent distribution deals illustrate demand for its technology."|